Global Minimal Residual Disease Testing Market - 2024-2031

Global Minimal Residual Disease Testing Market - 2024-2031

The global minimal residual disease testing market reached US$YY million in 2023 and is expected to reach US$YY million by 2031, growing at a CAGR ofYY% during the forecast period 2024-2031.

Minimal residual disease (MRD) refers to the small number of cancer cells in the body especially blood post-treatment. A positive MRD indicates the presence of cancerous cells and chances of relapse, whereas a negative MRD indicates complete remission. Minimal residual disease testing helps measure treatment effectiveness, predict relapse risk, confirm remissions, and potentially detect early cancer return. MRD testing plays a crucial role in blood cancers like leukemia, lymphoma, and myeloma and is currently being studied for other cancer types.

Common tests used to detect MRD include flow cytometry, PCR, and NGS. These tests detect MRD using bone marrow and blood samples and can detect 1 cancer cell in 100,000 bone marrow cells.

Market Dynamics: Drivers

Rising importance of precision medicine in cancer treatment

Precision medicine, or personalized therapy, is a cancer treatment method that customizes treatment to an individual's genetics, lifestyle, tumor features, and microenvironment, providing a more effective alternative to traditional treatments. For tailoring a personalized treatment option, the physician uses lab-based tests such as NGS, PCR, etc. This also involves testing the minimal residual disease (MDR). This MDR testing is especially helpful in cases of highly recurrent forms of blood cancers such as chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL).

Patients with these conditions contain residual cancerous cells that cannot be detected by scans and hide over time to cause relapses. Hence MDR testing plays a crucial role in creating a precision therapy for patients who are at a risk of cancer recurrence. The Association of Cancer Care Centers has stated that minimal residual testing plays a crucial role in shaping treatment plans for cancer patients and improving overall patient management. With the rising emphasis on tailoring personalized medicine to cancer patients, the adoption of MDR testing is anticipated to increase and concurrently it's market growth.

For instance, on June 12, 2023, Myriad Genetics, Inc. announced a partnership with the University of Texas MD Anderson Cancer Center to assist in designing treatment plans and measure outcomes for metastatic renal cell carcinoma. For designing the precise treatment strategy the cancer center aims to use Myriad’s proprietary minimal residual disease (MDR) testing platform.

On June 13, 2023, a study published in the American Society of Clinical Oncology Journal stated that measurable residual disease testing has evolved in recent times and it is playing a crucial role in making clinical decisions in patients with ALL, AML, and CML precisely to tailor patient-specific treatment. Patients with positive MDR were at a higher risk of relapse even if a tailored treatment approach was employed. This indicates the importance of MDR testing in the prognosis of cancer therapy.

Moreover, the rising prevalence of leukemia, rising adoption of minimal residual disease testing in solid tumors, and rising investments in cancer research are expected to further boost the market growth.

Restraints

Factors such as the high cost of testing, and lack of standardized criteria for testing are expected to restrain the market growth.

For more details on this report - Request for Sample

Segment Analysis

The global minimal residual disease testing market is segmented based on type, technology, indication, end user and region.

The blood cancers in the indication segment accounted for approximately 80.29% of the global minimal residual disease testing market share

The minimal residual disease is majorly seen in cancers of blood and bone marrow, especially in chronic lymphocytic leukemia and acute myeloid leukemia. The occurrence of minimal residual disease is higher in leukemia patients due to continuous circulation of the blood in the body which increases the likelihood of residual cancer cells persisting in blood and bone marrow. Moreover, in the cancers of the bone marrow where blood production occurs continuously, the chance of developing residual cells is higher and the turnover of cell production is higher in the bone marrow. Right from its development, MRD testing has been used for the diagnosis and prognosis of leukemias and lymphomas. MRD testing plays a crucial role in early diagnosis, therapy monitoring, and relapse measurement in blood cancers.

For instance, in December 2022, an article published in Hematologica journal stated that minimal residual disease testing plays a crucial role as an independent predictor of relapse risk in patients with acute lymphoblastic leukemia (ALL). MRD testing is widely adopted for risk measurement in ALL patients and as a clinical decision support tool.

On April 18, 2024, according to an article published in Springer Nature, MRD testing is best suitable for detecting residual cells in blood cancers such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). MDR test is a promising approach for assessing the clinical prognosis and measuring the relapse risk in these types of cancers due to their well-defined molecular patterns.

Geographical Analysis

North America is expected to dominate the market with a 52.15% share in the global minimal residual disease testing Market

North America is expected to dominate the market due to its well-equipped healthcare facilities and diagnostic centers which can perform complex cancer screening. Moreover, research activities related to cancer are higher in the region due to favorable funding and high investments, which helps the manufacturers develop and launch novel techniques in MRD testing. In addition, several diagnostic companies specializing in cancer detection have their presence across the region and are providing access to patients all over the region. These diagnostic companies offer minimal residual testing in collaboration with top-tier hospitals to assist them in clinical and research settings.

On April 27, 2023, Foresight Diagnostics, Inc a U.S.-based company received funding of $58.75 million for the commercialization of its novel MRD testing portfolio “PhasED-Seq” which is based on ultrasensitive liquid biopsy. The company aims to use the funding for commercial-level development and launch in the region.

On September 25, 2023, Adela, Inc. received $48 million in funding for its proprietary MRD testing technology called genome-wide methylation used for the early detection of cancers. Adela plans to use the funding for commercial development of its MRD testing product.

Likewise, many companies investing or who have invested in MRD testing have received funding which is essential to launch and commercialize their product. Moreover, the stringent regulatory framework in the region ensures the high quality of the product when before it gets launched, which makes the manufacturers and innovators majorly focus on the North American market.

COVID-19 Impact Analysis

The COVID-19 pandemic has significantly impacted the global market for minimal residual disease testing. Due to imposed restrictions on movement, the timely diagnosis and treatment of patients with leukemia was delayed. As a result, several treatment procedures such as stem cell transplantation especially from allogenic sources were markedly affected, due to which the risk of minimal residual disease has increased. Moreover, the pandemic has also greatly impacted cancer diagnosis due to the transfer of healthcare resources to infected patients causing delays in timely diagnosis of minimal residual disease.

For instance, on January 25, 2023, an article published in BLOOD RESEARCH stated that patients with acute myeloid leukemia have faced delays in treatment, especially with stem cell therapy. The reason is the health concerns of the donor and receiver. Stem cell transplantation cannot be done if either the donor or recipient is infected with COVID-19. As a result, the chance of developing minimal residual disease has increased in the recipients.

On January 03, 2023, a meta-analysis study published by the National Center for Biotechnology Information reported a 27% decrease in cancer diagnostic tests in 2020 as compared to the pre-pandemic period. North America has seen a decrease in cancer tests by 27.5%, Europe by 29.6%, and Asia by 25.4%.

Market Segmentation

By Type
• Test Kits
• Test Services

By Technology
• PCR Based
• Next-Generation Sequencing
• Flow-Cytometry
• Others

By Indication
• Blood Cancers
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
Chronic myeloid leukemia (CML)
Lymphomas
Multiple myeloma
Others
• Solid Cancers
• Others

By End Users
• Hospitals & Clinics
• Diagnostic Centers
• Cancer Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major players in the minimal residual disease testing market include Adaptive Biotechnologies Corp., ARUP Laboratories., Myriad Genetics, Inc., Guardant Health, Natera, Inc., HematoLogics, Inc., Laboratory Corporation of America® Holdings., Twist Bioscience., Invivoscribe, Inc. and Cytognos among others.

Why Purchase the Report?
• To visualize the global minimal residual disease testing market segmentation based on type, technology, indication, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of minimal residual disease testing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global minimal residual disease testing market report would provide approximately 70 tables, 63 figures, and 187 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies